Renal cell carcinoma is often a silent disease discovered only by accident
In short: Renal cell carcinoma accounts for over 90% of kidney cancers, yet it frequently remains asymptomatic in its early stages. Many cases are detected incidentally during routine exams for unrelated issues. Understanding its complex genetic landscape and the limitations of classic symptoms is essential for navigating this challenging diagnosis.
Renal cell carcinoma (RCC) originates in the renal epithelium and is characterized by significant intra-tumour heterogeneity. Genomic studies have identified distinct molecular subtypes, such as clear cell, papillary, and chromophobe RCC. The clear cell subtype, which is the most common, is notably associated with the loss of the VHL gene and chromosome 3p, which are considered truncal events in its development.
Historically, medical practitioners looked for a classic triad of symptoms: blood in the urine, flank pain, and an abdominal mass. However, this combination occurs in only 10% to 15% of cases and typically signals advanced disease. Today, the disease is often found incidentally. When symptoms do appear, they can include weight loss, fever, high blood pressure, or paraneoplastic syndromes caused by hormones produced by the tumor.
Treatment strategies are highly dependent on the stage of the cancer. Localized RCC (stages I and II) is often managed with surgery, such as partial or radical nephrectomy, or through active surveillance for small tumors. For metastatic disease, systemic treatments like immunotherapy and targeted therapies, including tyrosine kinase inhibitors, are used to slow growth. Survival rates vary dramatically based on the extent of the spread, ranging from 93% for local disease to 19% for distant metastasis.
The complexity of RCC is further compounded by its genetic diversity, which creates therapeutic barriers. Multiregion sequencing has revealed that different parts of the same tumor can harbor different mutations, a phenomenon known as branched evolution. This genetic variation necessitates ongoing research into biomarkers to better predict patient outcomes and refine the use of targeted therapies in clinical practice.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Renal cell carcinoma - Nature Reviews Disease Primers
- Also: What Are Renal Cell Carcinoma Symptoms?
- Also: Renal cell carcinoma
To cite this card, link to https://intellectplus.co.uk/app/science-renal-cell-carcinoma.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Human body & genes · More in Science · Latest · A–Z · All topics